dr. goy compares acalabrutinib with ibrutinib in mcl
Published 6 years ago • 254 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
1:00
dr. goy on acalabrutinib versus ibrutinib in mcl
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
1:06
dr. goy on promising data with acalabrutinib in mcl
-
1:25
dr. goy discusses single-agent ibrutinib in mcl
-
1:06
dr. goy on efficacy with ibrutinib in mcl
-
1:46
dr. o'connor on acalabrutinib versus ibrutinib in mcl
-
1:09
dr. goy discusses ibrutinib with venetoclax in mcl
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
0:53
andre goy, md, discusses the best strategy for using ibrutinib in mcl
-
1:58
dr. shah compares toxicity profiles of ibrutinib and acalabrutinib
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
1:25
dr. abedin discusses differences between acalabrutinib and ibrutinib in cll
-
1:14
rationale for combining acalabrutinib with bendamustine and rituximab in mcl
-
0:58
dr. leslie on the benefits with zanubrutinib in mcl
-
1:07
dr. wang on addition of acalabrutinib to bendamustine/rituximab in mcl
-
1:50
dr. mato on ibrutinib versus acalabrutinib in cll
-
1:32
selecting btk inhibitors for patients with mcl
-
1:45
dr. patel discusses promise of acalabrutinib in mcl